* Bio Path Holdings Inc BPTH.OQ BPTH.O is expected to show
no change in quarterly revenue when it reports results on
November 12.
* Refinitiv's mean analyst estimate for Bio Path Holdings Inc
is for a loss of 33 cents per share. For the same quarter last
year, the company reported a loss of 80 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Bio Path
Holdings Inc is $12.5, about 61.4% above its last closing
price of $4.82.
This summary was machine generated November 10 at 11:10 GMT.
All figures in US dollars unless otherwise stated